2027 QBP Ratings Recalculated: How to Decide Whether to Reopen Your Bid Before June 22 — and How to Execute If You Do
CMS's recalculated 2027 QBP Ratings created one of the most time-sensitive decisions Medicare Advantage organizations faced this year: whether reopening a bid was worth the operational effort required to capitalize on a higher rating.
For some plans, a higher rating represented an opportunity to improve benchmarks and rebate revenue. For others, the operational complexity, compressed timelines, and broader product strategy considerations made the decision far less straightforward.
In this recorded webinar, industry experts discuss how plans evaluated the financial, strategic, and operational implications of reopening their bids and the key questions organizations needed to answer before moving forward. The discussion also explores what it takes to execute successfully, including benefit design considerations, vendor readiness, internal stakeholder alignment, and implementation planning.
Watch the recording to hear practical perspectives on one of the most consequential Medicare Advantage decisions of the year.
During this 60-minute webinar recording, you will:
- Learn how to evaluate whether reopening a bid creates meaningful financial value
- Understand the key revenue, benefit, and competitive implications of a higher QBP rating
- Identify the internal stakeholders (actuarial, product, finance, compliance, operations, and vendor management) who need to be in the room
- Explore the operational and strategic tradeoffs of reopening versus staying the course
- Gain a practical framework for assessing your organization's options before June 22
- Learn what plans need to consider operationally if they choose to reopen their bids, including benefit changes, vendor readiness, and implementation timelines
- Bring your questions for a live discussion on the financial, operational, and strategic considerations shaping bid decisions before the June 22 deadline
- Hear expert perspectives on one of the most time-sensitive Medicare Advantage decisions of the year
